Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 13 clinical trials
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This

monoclonal antibody therapy
cytarabine
methotrexate
chemotherapy regimen
mercaptopurine
  • 56 views
  • 04 Oct, 2022
  • 120 locations
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

ALLTogether collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several …

inotuzumab
doxorubicin
imatinib
dexamethasone
vincristine
  • 74 views
  • 04 Oct, 2022
  • 61 locations
Venetoclax Plus Inotuzumab for B-ALL

This research study is evaluating the safety and efficacy of administering venetoclax and inotuzumab ozogamicin in combination in patients with acute lymphoblastic leukemia (ALL) The

graft versus host disease
cancer chemotherapy
flow cytometry
tyrosine
lymphocytic leukemia
  • 1 views
  • 27 Oct, 2021
  • 2 locations
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

This trial is a limited multi-center, Phase II study to evaluate inotuzumab ozogamicin (Besponsa) in pediatric patients with MRD positive CD22-positive B-lymphoblastic leukemia (B-ALL

graft versus host disease
conjugated bilirubin
cytarabine
prednisolone
methotrexate
  • 10 views
  • 13 May, 2022
  • 1 location
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

The goal of this phase II clinical study is to learn about the safety of inotuzumab ozogamicin when given with fludarabine, with or without bendamustine, melphalan, and rituximab before and

carbon monoxide
antithymocyte globulin
monoclonal antibody therapy
methotrexate
ejection fraction
  • 2 views
  • 21 Apr, 2022
  • 1 location
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

This research study will add an anti-cancer drug (called inotuzumab ozogamicin also known as "InO") to treatment for participants with newly diagnosed Philadelphia chromosome-positive (Ph

  • 0 views
  • 24 May, 2022
  • 1 location
Phase II Study of Inotuzumab Ozogamicin in Patients With B-Cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease

This phase II trial studies how well inotuzumab ozogamicin works in treating patients with B-cell acute lymphocytic leukemia with positive minimal residual disease. Inotuzumab ozogamicin is a

monoclonal protein
monoclonal antibody therapy
flow cytometry
monoclonal antibodies
lymphocytic leukemia
  • 15 views
  • 11 Oct, 2022
  • 1 location
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back

  • 0 views
  • 13 Oct, 2022
  • 78 locations
Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL (ALL-001)

In the proposed study, escalating doses of inotuzumab ozogamicin will be added to a standard pediatric inspired re-induction regimen and administered to patients with relapsed or refractory B

cytarabine
methotrexate
ejection fraction
philadelphia chromosome
flow cytometry
  • 0 views
  • 04 Oct, 2022
  • 4 locations
Phase I/II Study of the Combination of Inotuzumab Ozogamycin (CMC-544) With Low-Intensity Chemotherapy in Patients With Acute Lymphoblastic Leukemia (ALL)

This phase I/II trial studies the side effects and best dose of inotuzumab ozogamicin and to see how well it works when given together with combination chemotherapy in treating patients with

carbon monoxide
anthracyclines
monoclonal antibody therapy
methotrexate
ejection fraction
  • 38 views
  • 28 Oct, 2022
  • 1 location